Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies

BACKGROUND: To investigate, retrospectively, the role of tumour histotype and antiangiogenic drugs for venous thromboembolism (VTE) development in advanced cancer patients treated in phase I studies. METHODS: Patients enrolled and treated in phase I studies conducted by SENDO (Southern Europe New Dr...

Descripción completa

Detalles Bibliográficos
Autores principales: Mandalà, M, Grosso, F, Vitalini, C, Corradino, I, Sanfilippo, R, Colombini, S, Clerici, M, Labianca, R, De Pascale, A, Marsoni, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419966/
https://www.ncbi.nlm.nih.gov/pubmed/22828607
http://dx.doi.org/10.1038/bjc.2012.325

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419966/
https://www.ncbi.nlm.nih.gov/pubmed/22828607
http://dx.doi.org/10.1038/bjc.2012.325

Ejemplares similares